Search Results for "President CEO Epicentre Biotechnologies"

01:58 EST 26th November 2015 | BioPortfolio

Matching Channels

Drug Development for Rare Diseases

The economics of any industry relies on a large demand for a particular product; this applies to the pharmaceutical industry where efforts are focused on big and relatively straight-forward diseases...

Matching News

Better hygiene in schools in Ebola epicentre pays off: UN

Better hygiene in schools in Liberia, Sierra Leone and Guinea—the epicentre of the Ebola epidemic—has dramatically cut infections among teachers and students, the UN said on Wednesday.

AXIM Biotechnologies Clarifies Relationship With Medical Marijuana, Inc. and CanChew Biotechnologies, LLC

NEW YORK, July 31, 2015 (GLOBE NEWSWIRE) -- A statement from AXIM Biotechnologies (OTC:AXIM), an innovative biotechnology company: "We have received numerous telephone calls from the public leading...

Avalanche Biotechnologies tanks on decision not to proceed to Phase IIb with AVA-101

Avalanche Biotechnologies (Nasdaq: AAVL) on Friday unexpectedly reported that, following further analyses…

Immatics US launches with $40mm Series A investment from parent Immatics Biotechnologies

Cancer immunotherapies developer Immatics Biotechnologies GMBH and the University of Texas MD Anderson Cancer Center together launched Immatics US Inc., a new adoptive cellular therapeutics (ACT) subs...

Benitec inks deal with China's Biomics Biotechnologies

Biospectrum Benitec acquires full rights to pre-clinical hepatitis B program from Biomics Biotechnologies [Read more]

Adaptive Biotechnologies to open East Coast office

Seattle-based Adaptive Biotechnologies plans to establish an office in New York City to house its business development and co -More- 

AVALANCHE BIOTECHNOLOGIES, INC. SHAREHOLDER UPDATE: Kessler Topaz Meltzer & Check, LLP Announces Update to Class Action and Reminds Avalanche Biotechnologies, Inc. Shareholders of Impending Deadline -- AAVL

RADNOR, Pa., Sept. 01, 2015 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Avalanche Biotechno...

Aelan enters Dx partnership with Nuclea Biotechnologies

A partnership deal was reached between Aelan Cell Technologies and Nuclea Biotechnologies to create, commercialize and suppor -More- 

Matching PubMed Articles

Search Whole site using Google


Advertisement Advertisement